Literature DB >> 10976976

Hypereosinophilia induced by high-dose intratumoral and peritumoral mistletoe application to a patient with pancreatic carcinoma.

R Huber1, H Barth, A Schmitt-Gräff, R Klein.   

Abstract

UNLABELLED: A patient with inoperable adenocarcinoma of the pancreas was treated with intraperitumoral and peritumoral injections of a Viscum album L. extract containing 5,700 ng/mL mistletoe lectin, mainly mistletoe lectin 1 (Abnobaviscum Quercus 2) for 5 weeks (1 injection per week). After the third injection (day 22), a marked eosinophilia was observed (1,800 per microliter) that rose to 3,268 per microliter after the fifth injection (day 42). Furthermore, histology performed on day 28 revealed accumulation of eosinophils in ductal lesions and adjacent stroma in addition to the features of ductal adenocarcinoma. In order to investigate whether eosinophilia correlated with immunological features, we analyzed cytokine production of peripheral blood mononuclear cells (PBMC) from this patient after stimulation with antigens known to "unmask" an individual's predisposition for defined immunoreactions, namely purified protein derivative (PPD) as a stimulator of T-helper (TH1)1-cells and tetanus toxoid (TT) as an activator of TH2-cells. PBMC of the patient showed a strong proliferation and production of interleukin (IL)-5 and IL-10 after incubation with TT indicating a type-2 response. Simultaneously, PBMC were induced to proliferate and produce interferon gamma (IFN-gamma) by incubation with PPD suggesting also a type-1 response. These data would readily explain the eosinophilia because eosinophils are effector cells of type-2 reaction but also require type-1 cytokines. Although the overall clinical course of the patient was rapidly progressive, temporary stabilization of the patient's general condition during mistletoe treatment was observed. It is, however, still an open question whether this transient benefit was due to the induction of eosinophilia by a type-2 response.
CONCLUSION: Before high-dose intratumoral and peritumoral treatment with a Viscum album L. extract containing mistletoe, lectin 1 can be associated with hypereosinophilia and strong production of TH1 as TH2 cytokines as well.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10976976     DOI: 10.1089/10755530050120664

Source DB:  PubMed          Journal:  J Altern Complement Med        ISSN: 1075-5535            Impact factor:   2.579


  7 in total

Review 1.  Herbal therapy use by cancer patients: a literature review on case reports.

Authors:  Oluwadamilola Olaku; Jeffrey D White
Journal:  Eur J Cancer       Date:  2010-12-23       Impact factor: 9.162

2.  Subcutaneous inflammation mimicking metastatic malignancy induced by injection of mistletoe extract.

Authors:  A I Finall; S A McIntosh; W D Thompson
Journal:  BMJ       Date:  2006-12-23

3.  Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy.

Authors:  Gil Bar-Sela; Nissim Haim
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

4.  Eosinophilic Pancreatitis Diagnosed With Endoscopic Ultrasound.

Authors:  Samir Kakodkar; Hina Omar; Julio Cabrera; Kenneth Chi
Journal:  ACG Case Rep J       Date:  2015-07-09

5.  Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study.

Authors:  Megan L Steele; Jan Axtner; Antje Happe; Matthias Kröz; Harald Matthes; Friedemann Schad
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-15       Impact factor: 2.629

6.  Triterpenoids amplify anti-tumoral effects of mistletoe extracts on murine B16.f10 melanoma in vivo.

Authors:  Christian M Strüh; Sebastian Jäger; Astrid Kersten; Christoph M Schempp; Armin Scheffler; Stefan F Martin
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

7.  Long-Term Survival of a Patient with Recurrent Dedifferentiated High-Grade Liposarcoma of the Retroperitoneum Under Adjuvant Treatment with Viscum album L. Extract: A Case Report.

Authors:  María Reynel; Yván Villegas; Paul G Werthmann; Helmut Kiene; Gunver S Kienle
Journal:  Integr Cancer Ther       Date:  2021 Jan-Dec       Impact factor: 3.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.